Survivin(g) adult T-cell leukemia/lymphoma.

In this issue of ONCOLOGY, Tobinai reviews the management of human T-cell lymphotropic virus type 1 (HTLV-1)–associated adult T-cell leukemia/lymphoma (ATL). Although rare in the United States, an estimated 10 to 20 million people are infected with HTLV-1 worldwide and 2% to 5% will develop ATL.[1] The prevalence of HTLV-1 infection and the consequent poor prognosis of ATL mark the disease as a public health issue in many countries. Prevention of transmission will ultimately eliminate disease associated with HTLV-1 infection.